ZA200306122B - The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment. - Google Patents

The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment.

Info

Publication number
ZA200306122B
ZA200306122B ZA200306122A ZA200306122A ZA200306122B ZA 200306122 B ZA200306122 B ZA 200306122B ZA 200306122 A ZA200306122 A ZA 200306122A ZA 200306122 A ZA200306122 A ZA 200306122A ZA 200306122 B ZA200306122 B ZA 200306122B
Authority
ZA
South Africa
Prior art keywords
antigestagens
infertility treatment
maturation during
endometrial maturation
during infertility
Prior art date
Application number
ZA200306122A
Other languages
English (en)
Inventor
Christa Hegele-Hartung
Henning M Beier
Holger Hess-Stumpp
Claudia Krusche
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of ZA200306122B publication Critical patent/ZA200306122B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200306122A 2001-01-09 2003-08-07 The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment. ZA200306122B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75628601A 2001-01-09 2001-01-09

Publications (1)

Publication Number Publication Date
ZA200306122B true ZA200306122B (en) 2004-11-08

Family

ID=25042810

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200306122A ZA200306122B (en) 2001-01-09 2003-08-07 The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment.

Country Status (8)

Country Link
US (1) US20020143000A1 (xx)
KR (1) KR20030070096A (xx)
EA (1) EA008057B1 (xx)
PE (1) PE20020804A1 (xx)
PT (1) PT1365765E (xx)
UA (1) UA80529C2 (xx)
YU (1) YU55403A (xx)
ZA (1) ZA200306122B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006054535A1 (de) * 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
DE19860719A1 (de) * 1998-12-23 2000-06-29 Schering Ag Neue Testosteronderivate und ihre Verwendung zur Langzeittherapie von Androgen-abhängigen Erkrankungen

Also Published As

Publication number Publication date
YU55403A (sh) 2006-03-03
US20020143000A1 (en) 2002-10-03
EA008057B1 (ru) 2007-02-27
UA80529C2 (en) 2007-10-10
EA200300750A1 (ru) 2003-12-25
PE20020804A1 (es) 2002-10-03
PT1365765E (pt) 2007-10-17
KR20030070096A (ko) 2003-08-27

Similar Documents

Publication Publication Date Title
HK1048073A1 (en) Use of xenon for treating neurointoxications.
IL141063A0 (en) Fsh mimetics for the treatment of infertility
PL364995A1 (en) Method for the treatment or prevention of flavivirus
EP1446114A4 (en) COMPOSITIONS AND METHODS FOR TREATING OSTEOPOROSIS
PL371192A1 (en) Polymer derivatives for treating metals
EP1465968A4 (en) METHODS OF TREATING DISTILLATE DEODORIZER
EP1442062A4 (en) METHOD FOR TREATING CARCINOMA
ZA200306122B (en) The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment.
MXPA02012907A (es) Procedimiento para encontrar compuestos que son adecuados para el tratamiento y/o la profilaxia de la obesidad.
MXPA03006156A (es) El uso de antigestagenos para inhibir la maduracion endometrial acelerada durante el tratamiento de infertilidad.
EP1461030A4 (en) AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA
IL150837A0 (en) Use of fsh for treating infertility
HK1050897A1 (en) Pyranoindoles for treating glaucoma
EP1435979A4 (en) METHODS OF TREATING MULTIPLE SCLEROSIS
PT1383578E (pt) Inibidor da aromatase em dose única para tratamento da infertilidade
AU2002332426A8 (en) Processes and apparatus for the manufacture of polynuclear aluminum compounds and disinfectants, and polynuclear aluminum compounds and disinfectants from such processes and apparatus
PL371270A1 (en) Substituted 2-pyrrolidine-2-yl-1h-indole derivatives for the treatment of migraine
GB0105581D0 (en) Cask treatment
HK1064947A1 (en) Use of non-feminizing estrogens as retinoprotecti ve agents for the treatment of glaucoma
GB0115693D0 (en) Vaporization apparatus
HK1049477A1 (en) Apparatus for beauty treatment.
HUP0500698A2 (en) Use of an ascomycin for the treatment of blepharitis
TW521666U (en) Remainder treatment device for kitchen remainder
GB0102559D0 (en) Treatment for angiogenesis-dependant condition
ZA200205558B (en) Use of FSH treating infertility.